BLOOD plasma, fibrinogen, and fibrin have long been explored for their role in skin tissue engineering and dermatological treatments, with promising preclinical results—but clinical adoption remains limited. A new systematic review evaluates 147 preclinical and 17 clinical studies to assess the effectiveness of these biomaterials in treating various skin conditions, from surgical wounds to severe burns.
Preclinical studies overwhelmingly support the use of blood plasma and fibrin-based biomaterials as wound dressings or monolayer skin substitutes, often combined with materials like agarose, polyethylene glycol, or collagen to enhance wound healing. These strategies show particular promise for excisional and surgical wounds, demonstrating significant regenerative potential. However, the transition to clinical practice has been slow.
The review highlights that while blood plasma-based treatments have been successfully applied in severely burned patients as bilayer skin substitutes or wound dressings, the number of clinical studies remains disproportionately low compared to preclinical research. Despite clear evidence of safety and efficacy, the absence of standardized treatment protocols and varied approaches to formulation have hindered widespread clinical adoption.
Over the past 15 years, research into plasma-based dermatological treatments has surged, yet translation into routine clinical use is still lagging. Experts emphasize the need for more clinical trials to establish standardized wound healing strategies tailored to specific dermatological conditions. As the field advances, overcoming these challenges could position blood plasma and fibrin biomaterials as a key innovation in skin regeneration and wound management.
Reference:
Anaya Malik | AMJ
